NCT07342478 2026-01-16ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLNewave Pharmaceutical IncPhase 3 Not yet recruiting306 enrolled